Cechetto, Lisa M.,Young, David S. F.,McConkey, Fortunata,Hahn, Susan E.,Findlay, Helen P.
申请号：
AU2008255527
公开号：
AU2008255527B2
申请日:
2008.05.23
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
CD44, a single chain hyaluronic acid (HA) binding glycoprotein, is expressedin a variety of normal tissues, all hematopoietic cells and several cancer tissues.A monoclonal antibody against CD44 from the hybridoma H460-16-2, depositedwith the ATCC as PTA-4621, was previously shown to be a cancerous disease modifyingantibody (CDMAB), preventing tumour growth and reducing tumour burden in cancermodels including prostate and breast cancer by cytotoxicity. The variable regionsof this monoclonal antibody were also isolated and sequenced to generate a chimericantibody that had improved anti¬ cancer activity over the monoclonal antibody.Now, humanized antibodies are generated that have similar CD44 binding activityas the parent PTA-4621 monoclonal antibody. The monoclonal, chimeric and humanizedantibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines,interferons, target or reporter moieties and hematogenous cells to treat cancer.These antibodies are also used in binding assays to determine CD44 expressionon cells.
